Evidence map›Paper›PMID 39934888›Full record

ArticleStem cell research & therapy2025

Human hair follicle-derived mesenchymal stem cells improve ovarian function in cyclophosphamide-induced POF mice.

Jinhua Mo, Hong Hu, Pengdong Li, Yang Ye, Wanle Chen, Lei Chen, Jing Qiao, Xiaoying Zhao, Qiuxia Yan, Cairong Chen

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jinhua Mo *Center for Reproductive Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, No. 35, Yinquan North Road, Qingcheng District, Qingyuan, 511518, Guangdong, China.
Hong Hu *Center for Reproductive Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, No. 35, Yinquan North Road, Qingcheng District, Qingyuan, 511518, Guangdong, China.
Pengdong Li *Center for Reproductive Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, No. 35, Yinquan North Road, Qingcheng District, Qingyuan, 511518, Guangdong, China.
Yang YeCenter for Reproductive Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, No. 35, Yinquan North Road, Qingcheng District, Qingyuan, 511518, Guangdong, China.
Wanle ChenCenter for Reproductive Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, No. 35, Yinquan North Road, Qingcheng District, Qingyuan, 511518, Guangdong, China.
Lei ChenCenter for Reproductive Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, No. 35, Yinquan North Road, Qingcheng District, Qingyuan, 511518, Guangdong, China.
Jing QiaoCenter for Reproductive Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, No. 35, Yinquan North Road, Qingcheng District, Qingyuan, 511518, Guangdong, China.
Xiaoying ZhaoCenter for Reproductive Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, No. 35, Yinquan North Road, Qingcheng District, Qingyuan, 511518, Guangdong, China.
Qiuxia YanCenter for Reproductive Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, No. 35, Yinquan North Road, Qingcheng District, Qingyuan, 511518, Guangdong, China. yanqiuxia1982@163.com.
Cairong ChenCenter for Reproductive Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, No. 35, Yinquan North Road, Qingcheng District, Qingyuan, 511518, Guangdong, China. cairong1222@163.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515220129Guangdong Medical Science and Technology Research Foundation B2023064open research funds from the Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University 202301-104open research funds from the Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University 202301-306Plan on enhancing scientific research in Guangzhou Medical University 2024SRP195Qingyuan People's Hospital Innovative Research Foundation 201904-10Scientific Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine 20241387
6 · The paper itself

Abstract

introductionMesenchymal stem cell (MSCs) of different tissue origins have become a new option for the treatment of premature ovarian failure (POF) as they can recovery the ovarian function. However, there were rarely researches about human hair follicle-derived mesenchymal stem cells (HF-MSCs) in POF.

objectivesIn this study, we compared the effects of HF-MSCs and human umbilical cord mesenchymal stem cells (HU-MSCs) on POF models to explore the underlying molecular mechanisms.

methodsFemale mice received intraperitoneal cyclophosphamid for 10 days to induce the POF mice model. One week after drug withdrawal, the mice were randomly divided into four groups according to the tail vein injection of drugs, which were: Control group (CON), Premature ovarian failure group (POF), HF-MSCs treatment group (P-H group) and HU-MSCs treatment group (P-U group). Which Treatment once a week for 4 consecutive times. Serum and ovarian tissues were collected 2 weeks after the last treatment, and fertility was performed by mating. ELISA, HE staining, transmission electron microscopy (TEM) were applied to evaluate the ovarian function, oocytes quantity and quality, and the mechanism was verified by qRT-PCR and western blot. In addition, the tumorigenic risk of organs was assessed by long-term observation.

resultsThe POF mice model was successfully established by intraperitoneal injection of cyclophosphamide 100 mg/kg/d for 10 days. Compared with POF group, two weeks after transplantation, serum FSH decreased, AMH and E2 increased in the P-H and P-U groups of mice (p < 0.05), but there was no significant difference between the P-H and P-U groups (p > 0.05). In addition, the number of primary follicles, secondary follicles and antral follicles in both P-H and P-U groups were significantly increased (p < 0.05), while the atretic follicles was significantly decreased (p < 0.05). The pups in POF group was significantly lower than that in P-H group and P-U group (p < 0. 01). Furthermore, those effects was more significant in P-H group than in P-U group (p < 0.05). In addition, the mitochondrial ultramicrostructure of the ovaries in the four groups showed a significant difference in the mitochondrial morphologies and number. In the POF group, the mitochondria presented a spheroids structure with fewer numbers, serious vacuolation and a disordered mitochondrial cristae arrangement. Nevertheless, after MSCs transplantation into the P-H and P-U group, we could observe ameliorative mitochondrial cristae alignment and vacuolation, as well as a small number of long rod-like structures. Mechanism study showed that KEAP1 protein expression was decreased in the P-H group, which increased the nuclear translocation of NRF2 and upregulated the expression of downstream HO-1 protein. At last, the possibility of tumor development after transplantation of HF-MSCs was excluded by long-term observation and organ anatomical examination.

conclusionHF-MSCs can improve ovarian function in cyclophosphamide-induced POF mice, and the effects were superior to HU-MSCs. The underlying mechanism may by inhibiting ferroptosis of granulosa cells through KEAP1/NRF2/HO-1 pathway.

Indexed as

Hair FollicleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationOvaryPrimary Ovarian InsufficiencyAnimalsCyclophosphamideDisease Models, AnimalFemaleHumansMiceCyclophosphamideFerroptosisHF-MSCsHU-MSCsKEAP1/ NRF2/HO-1Premature ovarian failure

Identifiers

PMID39934888
PMCPMC11816600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.